Immunotherapy after kidney cancer surgery: can a blood test predict who stays Cancer-Free?
NCT ID NCT07657325
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the immunotherapy drug toripalimab can prevent kidney cancer from coming back in high-risk patients who have had their kidney removed. Researchers will also check if a blood test for minimal residual disease (MRD) can predict which patients benefit most. About 110 adults with high-risk renal cell carcinoma will receive toripalimab after surgery and be followed for cancer recurrence and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
toripalimab (an immunotherapy drug)
What this could lead to
If successful, this could show that toripalimab helps prevent kidney cancer from returning after surgery, and that a blood test (MRD) can identify which patients need it most.
What could go wrong
This is a single-arm study with no placebo group, so results may be less definitive. The drug may cause immune-related side effects, and not all patients may benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changyi Quan
RECRUITINGTianjin, Tianjin Municipality, 300211, China
Contact Phone: •••-•••-•••• Email: •••••@•••••